Showing results (111-120 of 126) with videos related to

Sort By:
Pageof 13
Cancer Research|June 11, 1999
Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in miceD L Gu, A M Gonzalez, M A Printz, et al.
Journal of Dairy Science|September 10, 2014
Technical note: Advantages and limitations of authenticating Palmera goat dairy products by pyrosequencing the melanocortin 1 receptor (MC1R) geneB Badaoui, A Manunza, A Castelló, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancerChau T Dang, Gabriella M D'Andrea, Mary E Moynahan, et al.
Journal of the American Heart Association|August 27, 2015
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical TrialPierluigi Tricoci, Denise M D'Andrea, Paul A Gurbel, et al.
American Journal of Clinical Pathology|October 13, 2021
Hantavirus Disease and COVID-19Allison K Joyce, Tarrah T Oliver, Aaron D Kofman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 7, 2024
In Vivo CRISPR Screening Reveals CHD7 as a Positive Regulator of Short-lived Effector CellsMartin W LaFleur, Jasmin M D'Andrea, Dillon G Patterson, et al.
Animal Genetics|December 6, 2013
Genome-wide analysis of Italian sheep diversity reveals a strong geographic pattern and cryptic relationships between breedsE Ciani, P Crepaldi, L Nicoloso, et al.
Circulation|November 25, 2016
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)C Michael Gibson, Serge Korjian, Pierluigi Tricoci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancerMaura N Dickler, Hope S Rugo, Carey A Eberle, et al.
Clinical Breast Cancer|October 12, 2015
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast CancerNeil M Iyengar, Monica N Fornier, Steven M Sugarman, et al.
Pageof 13